Germany reached an agreement with CureVac and GSK

Germany has signed a contract with CureVac and its British partner GSK for the supply of domestically produced mRNA vaccines until 2029 in case of public health emergencies, the German biotech firm said. The contract allows the production of up to 80 million doses in the short term.

Share this post:

Related Posts
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
WordPress Cookie Plugin by Real Cookie Banner